{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RBV%3A+24-week+treatment&page=5",
    "query": {
      "intervention": "RBV: 24-week treatment",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RBV%3A+24-week+treatment&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RBV%3A+24-week+treatment&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T02:46:59.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01525628",
      "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "caffeine",
          "type": "DRUG"
        },
        {
          "name": "tolbutamide",
          "type": "DRUG"
        },
        {
          "name": "pegylated interferon",
          "type": "DRUG"
        },
        {
          "name": "BI 207127",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 72,
      "start_date": "2012-04",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-10",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 5,
      "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525628"
    },
    {
      "nct_id": "NCT00575224",
      "title": "Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C",
        "Asian Americans",
        "Novel Genotypes",
        "Treatment"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon and ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacific Health Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-10",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2009-11-25",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 5,
      "location_summary": "San Diego, California • San Jose, California • Westminster, California + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00575224"
    },
    {
      "nct_id": "NCT01241760",
      "title": "VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Genotype 1 Chronic Hepatitis C",
        "Treatment Naive"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 744,
      "start_date": "2010-12",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 37,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 34 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241760"
    },
    {
      "nct_id": "NCT01768286",
      "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 441,
      "start_date": "2013-01",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 53,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768286"
    },
    {
      "nct_id": "NCT00087594",
      "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2003-11",
      "completion_date": "2006-10",
      "has_results": true,
      "last_update_posted_date": "2016-03-04",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Farmington, Connecticut • Honolulu, Hawaii + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Downers Grove",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087594"
    },
    {
      "nct_id": "NCT00743795",
      "title": "Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "GS-9190",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Alfa 2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 252,
      "start_date": "2008-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 48,
      "location_summary": "Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Clemente",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743795"
    },
    {
      "nct_id": "NCT01384383",
      "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "GS-5885",
          "type": "DRUG"
        },
        {
          "name": "GS-9451",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 248,
      "start_date": "2011-08",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-03",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384383"
    },
    {
      "nct_id": "NCT00980330",
      "title": "A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peg-IFN-alfa-2a (P)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tibotec Pharmaceuticals, Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 463,
      "start_date": "2009-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980330"
    },
    {
      "nct_id": "NCT01888900",
      "title": "New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cirrhosis",
        "Chronic Hepatitis C",
        "Hepatitis C",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "DUAL",
          "type": "DRUG"
        },
        {
          "name": "QUAD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2013-05",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-02-07",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01888900"
    },
    {
      "nct_id": "NCT01616524",
      "title": "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon lambda (pegIFNλ)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated interferon alfa-2a (pegIFNα-2a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2012-07",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-10-10T02:46:59.580Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616524"
    }
  ]
}